BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that its annual report and financial statements for the year ended 31 December 2021 (“Annual Report and Accounts”) are available for download on the Company’s investor-centre CLICK HERE; and confirms the date for its Annual General Meeting (“AGM”).

The Annual Report and Accounts will be mailed to shareholders, who have elected to opt out on receiving electronic communications, later today.

The Company will hold its AGM on Thursday, 31 March 2022 at 12:00pm GMT at the Company’s registered office, Mereside, Alderley Park, Alderley Edge, Cheshire, SK10 4TG.